PharmaTelevision Appoints Managing Director

OXFORD, England, March 29, 2010 – PharmaVentures, the global corporate advisory serving the biotechnology
and pharmaceutical industry, is pleased to announce the appointment of Anne
Vindenes Allen as Managing Director of its new subsidiary, PharmaTelevision
Ltd.

PharmaTelevision is the leading television company dedicated to assisting
biopharma companies in their business information and communication needs. In
addition [...]

CSL Limited Publishes First Corporate Responsibility Report

MELBOURNE, Australia, March 29, 2010 – CSL Limited (ASX: CSL), Australia's leading biopharmaceutical company,
has released its first Corporate Responsibility Report, combining information
about the Company's economic, social and environmental performance for 2009.

"CSL has experienced significant growth over the past 10 years, which has
been underpinned by our commitment to conducting our business [...]

Health Robotics Launches i.v.SOFT Global Beta Installation Program at the European Association of Hospital Pharmacists

BOZEN, Sud-Tirol, Italy, March 29, 2010 – Health Robotics today announced the successful global launch of the Beta
Installation kick-off for its 3 latest i.v.SOFT Workflow Engine software
automation modules [Assist, Label+ and Profile] in Nice [France], the 2010
venue for the European Association of Hospital Pharmacists. i.v.SOFT helps
Pharmacy Technicians, I.V. Room Supervisors, and Pharmacy Directors to
compound [...]

Hoya Corporation Appoints Chris Japp Global President of Hoya (Pentax) Lifecare Division

TOKYO, March 29, 2010 – Hoya Corporation announced the appointment of Chris N. Japp to the
position of Global President, Hoya (Pentax) Lifecare Division.

"Hoya Corporation is extremely pleased to have Chris Japp lead the global
division for Lifecare," said Hiroshi Hamada, COO of Hoya Corporation. "Chris
brings a wealth of knowledge, insight and [...]

Sanofi-aventis: Multaq(R) Receives Positive Recommendation by NICE in New Appraisal Consultation Document

PARIS, March 30, 2010 – Sanofi-aventis (EURONEXT: SAN, and NYSE: SNY) announced today
that the National Institute for Health and Clinical Excellence (NICE) in
England and Wales, has just published a new appraisal consultation document
(ACD)[1] for Multaq(R) (dronedarone) indicating its intention to recommend
Multaq(R) use for the management of patients with atrial fibrillation (AF).

[...]